What I am working with: Janoshik · a GLP-1 receptor agonist.
This is a procedural question rather than a theoretical one, and I would like the procedure rather than the theory.
What I have done so far is read the label documentation where it exists and the two pharmacopoeial monographs that are publicly available, which cover the licensed presentation and say nothing about a research one.
What is the correct sequence, and where is the step that people usually skip?
The failure mode here is publishing a result that applies to the tested vial alone while implying it applies to the entire lot.
The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.
| Component | Typical share | Counted in purity? | Counted in content? |
|---|---|---|---|
| Target peptide | 88–94 % | Yes, as main peak | Yes |
| Related impurities | 1–3 % | Yes, as other peaks | No |
| Counter-ion (TFA or acetate) | 2–8 % | No | No |
| Residual water | 2–6 % | No | No |
| Bulking agent, if present | 0–40 % | No | No |
If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.
Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.
One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.
If testing multiple vials, state how many you tested and why you chose those vials.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemA certificate that reports one test result on one vial extrapolates to claim that all two hundred vials in the lot are identical, which is an assumption worth questioning.
If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.
To be exact about it, the statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
edited 26 May 2026 by anouk_desmet — updated for the 2026 guidance change
The single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.
If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.
For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.
Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.
Assume segregation is possible, and design your sampling to catch it if it exists.
edited 25 Jun 2026 by kwn_analytical — tightened the wording; no substantive change
Batch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.
Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.
If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.
Thermal history during shipping is different for every vial, so a lot that experienced thermal abuse may have internal variation even if it was originally homogeneous.
Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.
In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.